Lidocaine Aguettant

Lidocaine Hydrochloride, the active ingredient in Lidocaine Aguettant, is a local anesthetic presented as a sterile solution for infiltration, intradermal and intravenous use. It provides temporary loss of sensation for minor surgical or diagnostic procedures and can be used to manage certain cardiac arrhythmias. GNH USA supplies Lidocaine Aguettant as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lidocaine Aguettant acts on peripheral nerve sodium channels to produce reversible loss of sensation in several clinical settings. - Minor surgical or diagnostic procedures: provides infiltration anesthesia for temporary numbness of the targeted tissue. - Intradermal procedures: enables skin testing or minor dermatologic interventions with rapid onset. - Ventricular arrhythmias: administered intravenously to suppress ectopic ventricular activity in cardiac emergencies.

Lidocaine Aguettant may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Burning or stinging at the injection site - Dizziness or light‑headedness - Nausea or mild vomiting - Metallic taste in the mouth - Transient hypotension - Headache

Serious or Rare Side Effects: - Central nervous system toxicity (e.g., seizures, confusion) - Cardiac toxicity (e.g., arrhythmias, cardiac arrest) - Severe allergic reactions (e.g., anaphylaxis, rash) - Methemoglobinemia - Respiratory depression - Persistent hypotension requiring intervention

Before using Lidocaine Aguettant, clinicians should consider several safety measures. - Allergy assessment: verify no known hypersensitivity to amide‑type local anesthetics. - Cardiac monitoring: use caution in patients with conduction disorders or severe heart disease. - Dose calculation: ensure total administered dose does not exceed recommended maximums. - Concomitant CNS depressants: monitor for additive sedative effects. - Pregnancy and lactation: use only if the potential benefit justifies the potential risk. - Store at ambient temperature: keep in the original container, protect from light and moisture.

Lidocaine Aguettant can interact with other medications, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Class I antiarrhythmic agents (e.g., quinidine, procainamide): additive cardiotoxicity. - Other amide‑type local anesthetics: risk of cumulative systemic toxicity. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase plasma lidocaine concentrations.

Moderate Interactions (Monitor Closely): - Beta‑adrenergic blockers: may enhance bradycardia. - Diuretics (e.g., furosemide): can reduce plasma protein binding, raising free drug levels. - General anesthetics (e.g., propofol, volatile agents): additive central nervous system depression.